塞诺巴马特对情绪和发作频率的影响
Mert Karatas1, Alperan Yavuz2, Blake Newman2
1Department of Neurology, University of Utah, Salt Lake City, UT 84132, USA; Molecular Medicine Program, University of Utah, Salt Lake City, UT 84112, USA.
Epilepsy & behavior : E&B
|January 30, 2026
概括
塞诺巴 (CNB) 有效地降低了患者的发作频率,而没有恶化抑郁症状. 这项实践研究表明,CNB是一种安全有效的辅助治疗,用于控制发作.
科学领域:
- 和神经系统疾病
- 药理学和治疗学 药理学和治疗学
- 精神病学和心理健康 精神病学和心理健康
背景情况:
- 新批准的抗发作药物 (ASM) 需要进行现实世界的疗效和耐受性评估,因为这些可能与临床试验结果有所不同.
- 大约40%的患者 (PWE) 患有并发性抑郁症,需要评估新ASM的情绪相关影响.
- 塞诺巴 (CNB) 在受控试验中显示出显著的疗效,但其对现实世界患者情绪的影响需要进一步调查.
研究的目的:
- 评估辅助性 (CNB) 对耐药性焦点的成年患者情绪,耐受性和控制的实际影响.
- 用患者健康问卷-9 (PHQ-9) 评分来评估抑郁症状的变化.
- 分析发作频率的降低和发作自由率.
主要方法:
- 一个单一中心的回顾性图表审查成年患者的耐火焦发起CNB作为附加疗法 (五月2020-七月2023).
- 纳入标准:在CNB上≥3个月,在基线和随访时可用的发作频率,并配对PHQ-9分数.
- 通过对变化,log2折变化和百分比变化分析的发作结果;通过发作自由度定义的响应,≥50%或≥75%的发作减少.
主要成果:
- 73名成人PWE符合研究标准;中位数的发作频率从每30天的5降至1.5 (p<0.001),中位数减少了50%.
- 29%的患者在最后一次随访时 (中位数为488天) 实现了无发作.
- 患者健康问卷-9 (PHQ-9) 评分没有显著恶化 (中位数 ΔPHQ-9 = 0),共变量和情绪结果之间没有关联.
结论:
- 雪诺巴 (CNB) 是一种安全有效的辅助ASM,用于改善PWE的控制.
- CNB没有显著改变PHQ-9分数,这表明该队列中对抑郁症状的中性影响.
- 虽然改善控制可能会影响情绪,但个人的情绪影响变量突出了需要进一步研究的需要.
相关概念视频
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
981
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
981
01:08Antiepileptic Drugs: Sodium Channel Blockers
2.4K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.4K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
01:17Antiepileptic Drugs: Calcium Channel Blockers
1.7K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.7K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
01:20Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K